Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04787341 | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence | PHASE2 | ACTIVE NOT_RECRUITING | 214 | — | — | Dec 15, 2020 | Jun 30, 2026 | May 20, 2026 | 1 | Italy |
time from randomization to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive.
| Arm | Type | Description |
|---|---|---|
| Panitumumab followed by Regorafenib | ACTIVE_COMPARATOR | - |
| Regorafenib followed by Panitumumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Regorafenib | DRUG | regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
| Panitumumab | DRUG | panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
Inclusion Criteria: * Age ≥ 18 years. * Written informed consent to molecular analyses. * Histologically proven diagnosis of CRC. * At least one measurable lesion according to RECIST1.1 * ECOG PS ≤ 1. * mCRC previously treated for metastatic disease with, or not considered candidates for, fluoropyr...